CLINICAL_TRIALS ClinicalTrials.gov record update

Immunogenicity and Safety Study of GSK Biologicals' Priorix Vaccine (209762) at an End of Shelf-life Potency Compared to Merck & Co., Inc.'s Measles-mumps-rubella (MMR) Vaccine When Both Are Given on a 2-dose Schedule to Healthy Children in Their 2nd Year of Life

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01681992
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:52.447588+00:00
Published At: 2018-08-17T00:00:00+00:00
Record Updated At: 2021-01-07
Results Posted At: 2018-08-17
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Measles", "Mumps", "Rubella", "Measles-Mumps-Rubella Vaccine"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-01-07"
protocolSection.identificationModule.nctId: "NCT01681992"
protocolSection.identificationModule.officialTitle: "Immunogenicity and Safety Study of GSK Biologicals\u0027 Priorix Vaccine (209762) at an End of Shelf-life Potency Compared to Merck \u0026 Co., Inc.\u0027s Measles-mumps-rubella (MMR) Vaccine When Both Are Given on a 2-dose Schedule to Healthy Children in Their 2nd Year of Life"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2018-08-17"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.